ZP 10068
Alternative Names: ZP-10068Latest Information Update: 22 May 2024
At a glance
- Originator Zealand Pharma
- Developer Alexion AstraZeneca Rare Disease; Zealand Pharma
- Class Anti-inflammatories; Peptides
- Mechanism of Action Complement C3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation